It has become clear that you cannot discuss the future of global clinical research and its innovations without talking about South Korea. In our previous blog post, we delved into South Korea’s clinical research infrastructure, and found that it is among the best-equipped countries in the world for hosting clinical trials – with substantial governmental support, joint IRBs, and streamlined drug application and approval processes. In the second half of this series, we will discuss the prevalence of mobile health solutions in South Korea to determine what aspects of BBK’s mobile health initiatives resonate most with the population.
Today’s post will feature insights from our strategic global alliance partner at Inje Paik Clinical Trial Center in South Korea. Pioneers of the clinical R&D industry in the region, Inje Paik is transforming the clinical research study groundwork through innovative initiatives and programs, exclusive and robust investigator and patient networks, and creative strategies and technologies.
Active international collaboration has facilitated the rise of the Asia Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and South Korea – whose clinical research environments vary significantly from each other – share many common interests in their pursuit for advancing clinical R&D. The open flow of data between these countries, and their desire for expanding research, has resulted in a dynamic climate for conducting clinical trials.
Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable clinical trial landscapes in the world: South Korea.
On the heels of our recent post on our presence at this week’s DIA Japan 2015, BBK welcomes Philip Gregory, the General Manager of George Clinical - CRO China as our guest contributor. With more than 20 years of experience in pharmaceutical, biotech and medical device marketing, Mr. Gregory has spent over 14 years supporting the expansion of clinical trial capabilities in Asia. He will be providing his insights over the course of a three-part blog series on the growth of clinical research across the Asia Pacific region.
We are very excited to be attending next week’s 12th Annual Meeting DIA Japan 2015, to be held at Tokyo Big Sight in Tokyo, November 15 – 17. It’s the first time that many of us based here in our U.S. headquarters will be joining our Japan team since opening our new Tokyo office over the summer. Under the theme “Medicine Development” this year’s event is set to focus on the innovative and constructive influence of patients on the enterprise of clinical R&D – a topic that’s always at the center of our work here at BBK.
Choosing the right countries and sites for a particular study remains one of the industry’s biggest challenges – but it doesn’t have to be. When the time comes to select sites for your clinical research study, there are many considerations that can guide your decisions to ensure the best possible outcome.
Topics: Site Selection
A recent survey conducted on behalf of the National Institute for Health Research Clinical Research Network shows that 89% of people would be willing to take part in a clinical trial if they were diagnosed with a medical condition or disease. This figure has very positive implications for the enterprise of global clinical research, as patient enrollment is one of the defining aspects of its success. So why is it that half of all investigative sites under-enroll for patients, and 11% of sites fail to enroll a single patient for a clinical trial?
It’s award season, and we’re proud to announce a few new wins including an Rx Club Award and three American Graphic Design Awards, all for Creative Excellence. Congrats to our marketing and creative teams!
There are many variables to consider when creating an advertising campaign for your clinical research study, but among the most important is the decision of which mediums to deploy. It can be staggering to think about all of the ways in which your potential patients might learn about your clinical research opportunity, and deciding how to make your campaign most visible can be challenging.